{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-23-000063","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.562212+00:00","generated_at":"2026-06-11T17:40:07.682825+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Salarius explores strategic alternatives, cuts workforce >50% after Q2 net loss of $3.9M","bullets":["FDA removed partial clinical hold on seclidemstat Phase 1/2 Ewing sarcoma trial.","SP-3164 received FDA IND clearance for relapsed/refractory NHL Phase 1 trial.","Cash $11.5M as of June 30, expected to fund operations through Q4 2023.","Net loss Q2 2023 was $3.9M ($1.43/share) vs $4.7M ($2.20/share) in Q2 2022.","Implementing cost-savings plan with >50% workforce reduction to extend resources."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-23-000063","json":"https://secwatch.observer/filing/0001615219-23-000063.json","markdown":"https://secwatch.observer/filing/0001615219-23-000063.md","text":"https://secwatch.observer/filing/0001615219-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/0001615219-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/flks-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:40:07.682825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91977730fc43f9bc137519312de3801ae294c03f","claim":"Decoy Therapeutics Inc. reported three and six months ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share, EPS $1.43 per share.","evidence_excerpt":"reported financial results for the three and six months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/0001615219-23-000063-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share"},{"label":"EPS","value":"$1.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}